2021 Update of the International Council for Standardization in Haematology Recommendations for Laboratory Measurement of Direct Oral Anticoagulants

Abstract In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the...

Full description

Saved in:
Bibliographic Details
Published in:Thrombosis and haemostasis Vol. 121; no. 8; pp. 1008 - 1020
Main Authors: Douxfils, Jonathan, Adcock, Dorothy M., Bates, Shannon M., Favaloro, Emmanuel J., Gouin-Thibault, Isabelle, Guillermo, Cecilia, Kawai, Yohko, Lindhoff-Last, Edelgard, Kitchen, Steve, Gosselin, Robert C.
Format: Journal Article
Language:English
Published: Rüdigerstraße 14, 70469 Stuttgart, Germany Georg Thieme Verlag KG 01.08.2021
Subjects:
Anticoagulation Reversal - standards
Blood Coagulation - drug effects
Blood Coagulation Tests - standards
Consensus
Drug Monitoring - standards
Evidence-Based Medicine
Factor Xa Inhibitors - adverse effects
Factor Xa Inhibitors - blood
Factor Xa Inhibitors - therapeutic use
Hemorrhage - chemically induced
Hemorrhage - prevention & control
Humans
Point-of-Care Testing - standards
Predictive Value of Tests
Reproducibility of Results
Review Article
diagnosis management
direct oral anticoagulants
guidance
laboratory
ISSN:0340-6245, 2567-689X, 2567-689X
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract In 2018, the International Council for Standardization in Haematology (ICSH) published a consensus document providing guidance for laboratories on measuring direct oral anticoagulants (DOACs). Since that publication, several significant changes related to DOACs have occurred, including the approval of a new DOAC by the Food and Drug Administration, betrixaban, and a specific DOAC reversal agent intended for use when the reversal of anticoagulation with apixaban or rivaroxaban is needed due to life-threatening or uncontrolled bleeding, andexanet alfa. In addition, this ICSH Working Party recognized areas where additional information was warranted, including patient population considerations and updates in point-of-care testing. The information in this manuscript supplements our previous ICSH DOAC laboratory guidance document. The recommendations provided are based on (1) information from peer-reviewed publications about laboratory measurement of DOACs, (2) contributing author's personal experience/expert opinion and (3) good laboratory practice.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Instructional Material/Guideline-3
ObjectType-Review-4
content type line 23
ISSN:0340-6245
2567-689X
2567-689X
DOI:10.1055/a-1450-8178